Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

被引:34
|
作者
Ramus, Susan J. [2 ]
Antoniou, Antonis C. [1 ]
Kuchenbaecker, Karoline B.
Soucy, Penny [3 ,4 ]
Beesley, Jonathan [5 ]
Chen, Xiaoqing [5 ]
McGuffog, Lesley
Sinilnikova, Olga M. [6 ,7 ]
Healey, Sue [5 ]
Barrowdale, Daniel
Lee, Andrew
Thomassen, Mads [8 ]
机构
[1] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Cambridge CB1 8RN, England
[2] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[3] Univ Laval, Quebec City, PQ, Canada
[4] Ctr Hosp Univ Quebec, Canc Genom Lab, Quebec City, PQ, Canada
[5] Queensland Inst Med Res, Genet & Populat Hlth Div, Herston, Qld 4006, Australia
[6] Ctr Hosp Univ Lyon, Ctr Leon Berard, Unite Mixte Genet Constitut Canc Frequents, Lyon, France
[7] Univ Lyon 1, INSERM, CNRS, Ctr Rech Cancerol Lyon,U1052,UMR5286, F-69365 Lyon, France
[8] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark
基金
美国国家卫生研究院; 加拿大健康研究院; 芬兰科学院; 俄罗斯基础研究基金会; 澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
ovarian cancer; BRCA1; BRCA2; association; SNP; GENOME-WIDE ASSOCIATION; BREAST-CANCER; POPULATION; LOCUS; 8Q24; POSITION; 9P22.2; 1P11.2;
D O I
10.1002/humu.22025
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian cancer risk in BRCA2 carriers; rs10088218 per-allele hazard ratio (HR) = 0.81 (95% CI: 0.670.98) P-trend = 0.033, rs2665390 HR = 1.48 (95% CI: 1.211.83) P-trend = 1.8 x 10-4, rs717852 HR = 1.25 (95% CI: 1.101.42) P-trend = 6.6 x 10-4, rs9303542 HR = 1.16 (95% CI: 1.021.33) P-trend = 0.026. Two loci were associated with ovarian cancer risk in BRCA1 carriers; rs10088218 per-allele HR = 0.89 (95% CI: 0.810.99) P-trend = 0.029, rs2665390 HR = 1.25 (95% CI: 1.101.42) P-trend = 6.1 x 10-4. The HR estimates for the remaining loci were consistent with odds ratio estimates for the general population. The identification of multiple loci modifying ovarian cancer risk may be useful for counseling women with BRCA1 and BRCA2 mutations regarding their risk of ovarian cancer. Hum Mutat 33:690702, 2012. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:690 / 702
页数:13
相关论文
共 50 条
  • [41] Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families
    Kauff, ND
    Mitra, N
    Robson, ME
    Hurley, KE
    Chuai, S
    Goldfrank, D
    Wadsworth, E
    Lee, J
    Cigler, T
    Borgen, PI
    Norton, L
    Barakat, RR
    Offit, K
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (18): : 1382 - 1384
  • [42] Hereditary breast and ovarian cancer:: primary and secondary prevention for BRCA1 and BRCA2 mutation carriers
    Llort, Gemma
    Blanco, Merce Peris e Ignacio
    MEDICINA CLINICA, 2007, 128 (12): : 468 - 476
  • [43] The psychological impact of breast and ovarian cancer preventive options in BRCA1 and BRCA2 mutation carriers
    Borreani, C.
    Manoukian, S.
    Bianchi, E.
    Brunelli, C.
    Peissel, B.
    Caruso, A.
    Morasso, G.
    Pierotti, M. A.
    CLINICAL GENETICS, 2014, 85 (01) : 7 - 15
  • [44] Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival
    Biglia, Nicoletta
    Sgandurra, Paola
    Bounous, Valentina Elisabetta
    Maggiorotto, Furio
    Piva, Eleonora
    Pivetta, Emanuele
    Ponzone, Riccardo
    Pasini, Barbara
    ECANCERMEDICALSCIENCE, 2016, 10
  • [45] Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers
    Perri, Tamar
    Lifshitz, Dror
    Sadetzki, Siegal
    Oberman, Bernice
    Meirow, Dror
    Ben-Baruch, Gilad
    Friedman, Eitan
    Korach, Jacob
    FERTILITY AND STERILITY, 2015, 103 (05) : 1305 - 1312
  • [46] Predicting breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers using polygenic risk scores
    Kuchenbaecker, Karoline
    Simard, Jacques
    Offit, Kenneth
    Couch, Fergus J.
    Easton, Douglas F.
    Chenevix-Trench, Georgia
    Antoniou, Antonis C.
    CANCER RESEARCH, 2016, 76
  • [47] Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers
    Ramus, Susan J.
    Kartsonaki, Christiana
    Gayther, Simon A.
    Pharoah, Paul D. P.
    Sinilnikova, Olga M.
    Beesley, Jonathan
    Chen, Xiaoqing
    McGuffog, Lesley
    Healey, Sue
    Couch, Fergus J.
    Wang, Xianshu
    Fredericksen, Zachary
    Peterlongo, Paolo
    Manoukian, Siranoush
    Peissel, Bernard
    Zaffaroni, Daniela
    Roversi, Gaia
    Barile, Monica
    Viel, Alessandra
    Allavena, Anna
    Ottini, Laura
    Papi, Laura
    Gismondi, Viviana
    Capra, Fabio
    Radice, Paolo
    Greene, Mark H.
    Mai, Phuong L.
    Andrulis, Irene L.
    Glendon, Gord
    Ozcelik, Hilmi
    Thomassen, Mads
    Gerdes, Anne-Marie
    Kruse, Torben A.
    Cruger, Dorthe
    Jensen, Uffe Birk
    Caligo, Maria Adelaide
    Olsson, Hakan
    Kristoffersson, Ulf
    Lindblom, Annika
    Arver, Brita
    Karlsson, Per
    Askmalm, Marie Stenmark
    Borg, Ake
    Neuhausen, Susan L.
    Ding, Yuan Chun
    Nathanson, Katherine L.
    Domchek, Susan M.
    Jakubowska, Anna
    Lubinski, Jan
    Huzarski, Tomasz
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (02): : 105 - 116
  • [48] Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers
    Barnes, D. R.
    Antoniou, A. C.
    JOURNAL OF INTERNAL MEDICINE, 2012, 271 (04) : 331 - 343
  • [49] Contraceptive use and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers: A prospective cohort study.
    Xia, Yue Yin
    Lubinski, Jan
    Rosen, Barry
    Moller, Pal
    Eisen, Andrea
    Ainsworth, Peter
    Senter, Leigha
    Bordeleau, Louise
    Neuhausen, Susan L.
    Singer, Christian F.
    Brooks, Jennifer
    Sun, Ping
    Narod, Steven A.
    Kotsopoulos, Joanne
    CANCER RESEARCH, 2021, 81 (13)
  • [50] Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
    Kotsopoulos, Joanne
    Gronwald, Jacek
    McCuaig, Jeanna M.
    Karlan, Beth Y.
    Eisen, Andrea
    Tung, Nadine
    Bordeleau, Louise
    Senter, Leigha
    Eng, Charis
    Couch, Fergus
    Fruscio, Robert
    Weitzel, Jeffrey N.
    Olopade, Olufunmilayo
    Singer, Christian F.
    Pal, Tuya
    Foulkes, William D.
    Neuhausen, Susan L.
    Sun, Ping
    Lubinski, Jan
    Narod, Steven A.
    Huzarski, Tomasz
    Cybulski, Cezary
    Rosen, Barry
    Sweet, Kevin
    Zakalik, Dana
    Wood, Marie
    McKinnon, Wendy
    Elser, Christine
    Wiesner, Georgia
    Friedman, Eitan
    Meschino, Wendy
    Snyder, Carrie
    Metcalfe, Kelly
    Poll, Aletta
    Warner, Ellen
    Kim, Raymond
    Armel, Susan
    Demsky, Rochelle
    Ainsworth, Peter
    Steele, Linda
    Saal, Howard
    Serfas, Kim
    Panchal, Seema
    Cullinane, Carey A.
    Reilly, Robert E.
    Blum, Joanne L.
    Kwong, Ava
    Rayson, Daniel
    Ramon y Cajal, Teresa
    Dungan, Jeffrey
    GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 820 - 826